1. Home
  2. CSBR vs MAIA Comparison

CSBR vs MAIA Comparison

Compare CSBR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

HOLD

Current Price

$5.17

Market Cap

81.0M

Sector

Health Care

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.43

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSBR
MAIA
Founded
1985
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
79.0M
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
CSBR
MAIA
Price
$5.17
$1.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.3K
525.5K
Earning Date
03-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$2,900,000.00
N/A
Revenue This Year
$4.84
N/A
Revenue Next Year
$11.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.15
$0.87
52 Week High
$8.74
$3.19

Technical Indicators

Market Signals
Indicator
CSBR
MAIA
Relative Strength Index (RSI) 37.31 59.36
Support Level N/A $1.38
Resistance Level $6.31 $1.48
Average True Range (ATR) 0.29 0.07
MACD -0.06 0.01
Stochastic Oscillator 3.01 82.14

Price Performance

Historical Comparison
CSBR
MAIA

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: